Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

By Raffaella Sordella, D. Bell, D. Haber, J. Settleman. Science, 2004

1,654 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/80b47e819057cb298e40fa1b2a39f1723517bd3d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. P. Jänne
3. Adi F. Gazdar
4. Andrew K. Joe
5. Gregory Riely
6. Vincent A. Miller
7. H. Shigematsu
8. Gwen Macdonald

In Pathology and Forensic Medicine

1. N. Hynes
2. C. Sawyers

In Pulmonary and Respiratory Medicine

1. William Pao
2. Adi F. Gazdar
3. P. Jänne
4. Gregory Riely
5. Vincent A. Miller
6. M. Kris
7. N. Hynes
8. Gwen Macdonald

Citations in the corpus

• The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. (2015, background): “Gefitinib Gefitinib, an inhibitor of EGFR (ErbB1), has been approved for he treatment of non-small cell lung cancer (Pao et al., 2004; ordella et al., 2004).”
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (2006, background): “An experimental study indicated that mutations in the EGFR can preferentially enhance activation of the survival, Akt-associated pathway”
• Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data (2009, background): “H1666 and H3255 cell lines, which carry wild-type and mutant L858R ErbB1 receptors (Sordella et al , 2004; Tracy, 2004), respectively, were studied to ascertain whether the IERMv1.”
• Targeted cancer therapy (2004, methodology): “A third example is to use inhibitors of kinases in the PI(3)K/Akt/mTOR pathway to treat tumours with mutations in the tumour suppressor gene PTEN — the negative principal regulator of this pathway (see reviews in this issue by Massagué, page 298, and by Lowe et al.”
• ErbB receptors and signaling pathways in cancer. (2009, background): “Considering lung cancer, the prosurvival PI3K/Akt and STAT pathways appear to be hyperactive in the context of mutant EGFRs [25,26].”
• Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (2005, background): “Ligand-independent activation of EGFR with lung cancer-derived kinase domain mutations has not been observed by other groups working with transient transfection systems [22,27].”